Author

Daniel Paris

Scientist III, Head of Preclinical Research and Development, Roskamp Institute - Cited by 5,190 - Alzheimer's Disease - Neuroscience

Biography

Daniel Paris, MD, PhD, DTMH, is a clinical doctor, Associate Professor and Medical Director and Head of the Department of Medicine at Swiss TPH. His position incorporates the fusion of two predominantly service-oriented departments into a single medical department, with the addition of clinical translational research and diagnostic methodologies. Paris is a Swiss national, clinically trained at the University of Zurich. He spent many years working in clinical research in Southeast Asia for the University of Oxford, based in Bangkok as coordinator of clinical tropical medicine research with a focus on tropical rickettsial illnesses, diagnostics, clinical trials and causes-of-fever studies.
Title
Cited by
Year
α-Sheet secondary structure in amyloid β-peptide drives aggregation and toxicity in Alzheimer’s disease
D Shea, CC Hsu, TM Bi, N Paranjapye, MC Childers, J Cochran, ...Proceedings of the National Academy of Sciences 116 (18), 8895-8900, 2019201
125
2019
Lifelong behavioral and neuropathological consequences of repetitive mild traumatic brain injury
BC Mouzon, C Bachmeier, JO Ojo, CM Acker, S Ferguson, D Paris, ...Annals of clinical and translational neurology 5 (1), 64-80, 2018201
94
2018
The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation
D Paris, G Ait-Ghezala, C Bachmeier, G Laco, D Beaulieu-Abdelahad, ...Journal of Biological Chemistry 289 (49), 33927-33944, 2014201
67
2014
Role of the cannabinoid system in the transit of beta-amyloid across the blood–brain barrier
C Bachmeier, D Beaulieu-Abdelahad, M Mullan, D ParisMolecular and Cellular Neuroscience 56, 255-262, 2013201
57
2013
Distinct signaling pathways regulate TREM2 phagocytic and NFκB antagonistic activities
H Yao, K Coppola, JE Schweig, F Crawford, M Mullan, D ParisFrontiers in cellular neuroscience 13, 457, 2019201
51
2019
Stimulation of the retinoid X receptor facilitates beta-amyloid clearance across the blood–brain barrier
C Bachmeier, D Beaulieu-Abdelahad, F Crawford, M Mullan, D ParisJournal of Molecular Neuroscience 49, 270-276, 2013201
50
2013
Apolipoprotein E isoform-specific effects on lipoprotein receptor processing
C Bachmeier, B Shackleton, J Ojo, D Paris, M Mullan, F CrawfordNeuromolecular medicine 16, 686-696, 2014201
44
2014
Oleoylethanolamide treatment reduces neurobehavioral deficits and brain pathology in a mouse model of Gulf War Illness
U Joshi, JE Evans, R Joseph, T Emmerich, N Saltiel, C Lungmus, ...Scientific reports 8 (1), 12921, 2018201
42
2018
A permethrin metabolite is associated with adaptive immune responses in Gulf War Illness
U Joshi, A Pearson, JE Evans, H Langlois, N Saltiel, J Ojo, N Klimas, ...Brain, behavior, and immunity 81, 545-559, 2019201
41
2019
Chronic anatabine treatment reduces Alzheimer’s disease (AD)-like pathology and improves socio-behavioral deficits in a transgenic mouse model of AD
M Verma, D Beaulieu-Abdelahad, G Ait-Ghezala, R Li, F Crawford, ...PLoS One 10 (5), e0128224, 2015201
33
2015
Acute or delayed treatment with anatabine improves spatial memory and reduces pathological sequelae at late time-points after repetitive mild traumatic brain injury
S Ferguson, B Mouzon, D Paris, D Aponte, L Abdullah, W Stewart, ...Journal of neurotrauma 34 (8), 1676-1691, 2017201
27
2017
Targeting sirtuin activity with nicotinamide riboside reduces neuroinflammation in a GWI mouse model
U Joshi, JE Evans, A Pearson, N Saltiel, A Cseresznye, T Darcey, J Ojo, ...Neurotoxicology 79, 84-94, 2020202
26
2020
Chronic cerebrovascular abnormalities in a mouse model of repetitive mild traumatic brain injury
CE Lynch, G Crynen, S Ferguson, B Mouzon, D Paris, J Ojo, P Leary, ...Brain injury 30 (12), 1414-1427, 2016201
25
2016
Alzheimer’s disease pathological lesions activate the spleen tyrosine kinase
JE Schweig, H Yao, D Beaulieu-Abdelahad, G Ait-Ghezala, B Mouzon, ...Acta neuropathologica communications 5 (1), 1-, 2017201
25
2017
Spleen tyrosine kinase (SYK) blocks autophagic Tau degradation in vitro and in vivo
JE Schweig, H Yao, K Coppola, C Jin, F Crawford, M Mullan, D ParisJournal of Biological Chemistry 294 (36), 13378-13395, 2019201
23
2019
MMP9 modulation improves specific neurobehavioral deficits in a mouse model of Alzheimer’s disease
C Ringland, JE Schweig, M Eisenbaum, D Paris, G Ait-Ghezala, M Mullan, ...BMC neuroscience 22 (1), 1-25, 212
20
2021
Identification of telomerase-activating blends from naturally occurring compounds
G Ait-Ghezala, S Hassan, M Tweed, D Paris, G Crynen, Z Zakirova, ...Altern Ther Health Med 22 (Suppl 2), 6-14, 202
16
2016
Plasma cytokine IL‐6 levels and subjective cognitive decline: preliminary findings
AP Keegan, D Paris, CA Luis, L Abdullah, G Ait‐Ghezala, ...International journal of geriatric psychiatry 33 (2), 358-363, 2018201
13
2018
Apolipoprotein E isoforms differentially regulate matrix metallopeptidase 9 function in Alzheimer’s disease
C Ringland, JE Schweig, D Paris, B Shackleton, CE Lynch, M Eisenbaum, ...Neurobiology of aging 95, 56-68, 2020202
13
2020
Blood Pressure Lowering With Nilvadipine in Patients With Mild‐to‐Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension
RAA De Heus, R Donders, AMM Santoso, MGM Olde Rikkert, BA Lawlor, ...Journal of the American Heart Association 8 (10), e0938, 2019201
11
2019

Referred From: https://scholar.google.com/citations?user=TzGensIAAAAJ&hl=en&oi=ao

Cited by
Citations 5190
h-index 41
i10-index 80
Recommended Journals
Open Access Journals